Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 16.00 is 56% above its 5-year average of 10.25, around the middle of its 5-year range (1.02–45.15).
As of the fiscal period ended Tuesday, June 30, 2026. 3.77% below its 12-month average of 16.63.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 16.00.
QUICK RATIO (ACID-TEST)
16.00
QUICK RATIO (ACID-TEST) AVG TTM
16.63
QUICK RATIO (ACID-TEST) AVG 3Y
9.20
QUICK RATIO (ACID-TEST) AVG 5Y
10.25
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-3.77%
CURRENT VS 3Y AVG
+73.92%
CURRENT VS 5Y AVG
+56.16%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
+377.59%
vs the sector median at left
Eupraxia Pharmaceuticals Inc.
Market Cap
$262.99M
Quick Ratio (Acid-Test)
16.00
TTM Avg
16.63
3Y Avg
9.20
5Y Avg
10.25
Market Cap
$261.82M
Quick Ratio (Acid-Test)
7.68
TTM Avg
7.37
3Y Avg
6.66
5Y Avg
5.96
Market Cap
$261.08M
Quick Ratio (Acid-Test)
13.89
TTM Avg
8.37
3Y Avg
7.38
5Y Avg
15.00
Market Cap
$262.75M
Quick Ratio (Acid-Test)
24.26
TTM Avg
16.09
3Y Avg
10.56
5Y Avg
7.83
Market Cap
$260.65M
Quick Ratio (Acid-Test)
11.02
TTM Avg
6.66
3Y Avg
6.10
5Y Avg
6.28
Market Cap
$265.36M
Quick Ratio (Acid-Test)
4.46
TTM Avg
8.30
3Y Avg
6.73
5Y Avg
6.78
Market Cap
$264.75M
Quick Ratio (Acid-Test)
15.82
TTM Avg
24.04
3Y Avg
14.70
5Y Avg
12.06
Market Cap
$257.26M
Quick Ratio (Acid-Test)
0.93
TTM Avg
1.36
3Y Avg
5.78
5Y Avg
8.29
Market Cap
$256.40M
Quick Ratio (Acid-Test)
3.19
TTM Avg
3.85
3Y Avg
4.21
5Y Avg
4.14
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $262.99M | 16.00 | 16.63 | 9.20 | 10.25 |
| OraSure Technologies, Inc. (OSUR)vs › | $261.82M | 7.68 | 7.37 | 6.66 | 5.96 |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $261.08M | 13.89 | 8.37 | 7.38 | 15.00 |
| Palisade Bio, Inc. (PALI)vs › | $262.75M | 24.26 | 16.09 | 10.56 | 7.83 |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $260.65M | 11.02 | 6.66 | 6.10 | 6.28 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.36M | 4.46 | 8.30 | 6.73 | 6.78 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.75M | 15.82 | 24.04 | 14.70 | 12.06 |
| AC Immune S.A. (ACIU)vs › | $257.26M | 0.93 | 1.36 | 5.78 | 8.29 |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.40M | 3.19 | 3.85 | 4.21 | 4.14 |
| Scribe Therapeutics Inc. (SCTX)vs › | $269.43M | N/A | N/A | N/A | N/A |
Quick Ratio
16.00
Excludes inventory
Current Ratio
16.00
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 16.00 |
| 2026-03-31 | 19.30 |
| 2025-12-31 | 15.12 |
| 2025-09-30 | 23.98 |
| 2025-06-30 | 8.72 |
| 2025-03-31 | 13.00 |
| 2024-12-31 | 11.10 |
| 2024-09-30 | 4.17 |
| 2024-06-30 | 2.11 |
| 2024-03-31 | 1.95 |
| 2023-12-31 | 1.02 |
| 2023-09-30 | 1.75 |
| 2023-06-30 | 1.35 |
| 2023-03-31 | 8.82 |
| 2022-12-31 | 6.08 |
| 2022-09-30 | 13.66 |
| 2022-06-30 | 10.13 |
| 2022-03-31 | 21.10 |
| 2021-12-31 | 13.49 |
| 2021-09-30 | 12.03 |
| 2021-06-30 | 45.15 |
| 2021-03-31 | 4.21 |
| 2020-12-31 | 0.05 |
| 2020-09-30 | 0.03 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.13 |
| 2019-09-30 | 0.00 |
